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Abstract
Esophageal cancer is on the rise. The known precursor lesion is Barrett’s
esophagus (BE). Patients with dysplasia are at higher risk of developing
esophageal cancer. Currently the gold standard for surveillance endoscopy
involves taking targeted biopsies of abnormal areas as well as random biopsies
every 1-2 cm of the length of the Barrett’s. Unfortunately studies have shown that
this surveillance can miss dysplasia and cancer. Advanced imaging technologies
have been developed that may help detect dysplasia in BE. This opinion review
discusses advanced imaging in BE surveillance endoscopy and its utility in
clinical practice.
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Core tip: Barrett’s esophagus (BE) is a precursor of esophageal cancer, the incidence of
which is on the rise worldwide. Advanced imaging in BE includes dye
chromoendoscopy, electronic chromoendoscopy narrow band imaging (NBI), confocal
laser endomicroscopy and volumetric laser endomicroscopy (VLE). The decision to
perform these procedures ultimately depends on if the benefit outweighs the cost and any
added time performing the procedure. In our practice the added benefits of NBI and VLE
outweighs the costs and added time and thus we have incorporated this into our Barrett’s
surveillance routine.
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INTRODUCTION
Barrett’s esophagus (BE) is the development of specialized intestinal metaplasia in the
esophagus. The exact incidence of BE is not known, but it is estimated to be from
0.2%-2% per year[1]. It is a premalignant lesion for adenocarcinoma of the esophagus.
Though the rates of esophageal squamous cell carcinoma and distal gastric cancers are
declining, the incidence of esophageal adenocarcinoma is rising more than any other
malignancy[2]. Reports have quoted an average annual increase of up to 17%[2]. This
increase  may  be  due  to  environmental  and  population  factors,  but  also  due  to
insufficient detection of Barrett’s and insufficient surveillance protocols for patients
with known BE[3,4]. The Seattle protocol guides the surveillance procedure of many
endoscopists, which consists of 4-quadrant biopsies at intervals of every 1-2 cm and
separate samples of areas of mucosal irregularity, may miss a significant number of
areas of low-or high-grade dysplasia[5]. In a large multicenter study, 53% of patients
who underwent consecutive surveillance endoscopies documenting non-dysplastic
tissue or intestinal metaplasia without dysplasia, developed high grade dysplasia
and/or cancer within a mean of 3 years[1].
Unfortunately, the mortality for esophageal adenocarcinomas is very high, with a
mean 5-year survival rate of less than 20% for advanced disease. Many patients are
diagnosed at presentation with advanced disease, and there is a need to find better
means to identify patients at earlier stages. BE confers a 30-40 fold increased risk for
esophageal adenocarcinoma, but it  is  unclear if  such focus on surveillance in BE
patients has improved outcomes[2]. Patients with surveillance-detected BE have higher
rates of survival at two years compared to patients that are diagnosed outside of a
surveillance program (73.3% vs 12.5%, P = 0.02), yet few patients (3.9%) are diagnosed
with BE before their cancer diagnosis[2].  In other studies, there was no association
between  surveillance  in  BE  and  decreased  risk  of  death  from  esophageal  ade-
nocarcinoma (OR = 0.99; 95%CI: 0.36-2.75) and the detection of advanced disease was
equivalent in surveillance and non-surveillance groups[4].  Therefore,  current sur-
veillance strategies may be ineffective in improving patient outcomes.
Endoscopic  surveillance  of  known  BE  may  be  improved  through  advanced
imaging. Advanced imaging technologies allow visualization of abnormalities that
may not be seen on routine endoscopic evaluation. These are also termed as red flag
technologies as they point attention to abnormal areas that can be consistent with dys-
plasia or early cancer.
Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) was
developed in 2011 by the American Society of Gastrointestinal Endoscopy (ASGE) to
recognize important clinical questions and develop diagnostic and/or therapeutic
thresholds for endoscopic technologies related to these clinical questions[6]. In 2016,
performance thresholds  were  established to  evaluate  real-time imaging-assisted
modalities used for endoscopic targeted biopsies in the endoscopic surveillance of
non-dysplastic  BE which included chromoendoscopy (using acetic  acid and me-
thylene blue), electronic chromoendoscopy [using narrow-band imaging (NBI)], and
both probe and endoscopic based confocal laser endomicroscopy (CLE). Volumetric
laser endomicroscopy (VLE) was not evaluated in the PIVI initiative given the recent
release  on  the  market  at  the  time  and thus  lack  of  studies.  These  per-formance
thresholds included: (1) Sensitivity of ≥ 90% and a negative predictive value of ≥ 98%
for detecting high grade dysplasia (HGD) or early adenocarcinoma (EAC) compared
to standard protocol, and (2) Imaging technology with high (80%) specificity to allow
reduction  in  the  number  of  biopsies  compared  to  random biopsies.  Acetic  acid
chromoendoscopy, narrow band imaging and endoscopic CLE met the thresholds set
by the ASGE PIVI, and thus the ASGE Technology Committee endorsed using these
modalities to guide surveillance in patients with previously non-dysplastic BE.
Given the number of tools on the market, the main question to ask is, is it worth
performing any of these technologies? Ultimately it comes down to how cumbersome
is it to perform the technology compared to the yield of additional cases of dysplasia
being detected that changes management. Cost to the patient and health care system
is also a factor that can contribute to usage of a technology. We describe the tech-
nologies from these viewpoints in this mini-review.
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DYE CHROMOENDOSCOPY
Dye chromoendoscopy uses chemical agents to highlight mucosal changes of dys-
plasia to allow for improved detection of abnormalities[3]. Such dye agents include
methylene blue, indigo carmine and acetic acid. Methylene blue is absorbed by non-
dysplastic intestinal-type epithelium and can also be used to detect Barrett’s mucosa.
In several studies comparing rates of detection of intestinal metaplasia and dysplasia
between methylene blue and 4-quadrant biopsies, the rates for methylene blue were
similar than 4-quadrant biopsies, but the number of biopsies used to detect those
changes were lower with methylene blue[7]. Other studies have found four-quadrant
biopsies detect significantly more dysplasia than methylene blue[8]. In addition, there
is concern that methylene blue may damage DNA in Barrett’s epithelium potentially
leading to errors in diagnosis[9]. These solutions are difficult to handle and use en-
doscopically and therefore their use is not standard. Indigo carmine has also been
shown to be effective in detecting mucosal patterns, but when compared to high-
resolution white light endoscopy, indigo carmine showed no significant difference in
detecting early neoplasia[10,11]. Given its cumbersome use and lack of incremental yield
vs high definition white light endoscopy, its use is also not standard.
Acetic acid can be used to enhance different mucosal pit  patterns in columnar
epithelium. Certain pit patterns have shown high sensitivity and specificity for inte-
stinal  metaplasia.  In a meta-analyses,  acetic acid chromoendoscopy has shown a
sensitivity of 96.6%, negative predictive value of 98.3% and a specificity of 84.5% in
detecting dysplasia or esophageal adenocarcinoma[6].
Acetic acid is a safe, rapid, and inexpensive. It can highlight ridged and villous
patterns that are associated with mucosal abnormalities associated with dysplasia.
Therefore, its use is high yield in surveillance in BE[12].
ELECTRONIC CHROMOENDOSCOPY
Electronic chromoendoscopy techniques involve the use of NBI (Olympus America,
Center Valley, PA, United States) and I-Scan (Pentax Medical, Montvale, NJ, United
States).  Blue light imaging and linked color imaging (Fujifilm, Tokyo, Japan) are
newer electronic chromoendosocpy platforms. They will not be discussed here due to
limited data in Barrett’s esophagus. NBI highlights vascular patterns on the mucosal
surface by using spectral narrow-band optical fibers[13]. Figure 1 shows a patient with
Barrett’s and high-grade dysplasia with NBI imaging. I-Scan uses a post-processing
technology  to  highlight  contrast  between  squamous  and  columnar  epithelia[3].
Patterns detected by NBI have been shown to predict histology. In one study, a ridge/
villous pattern predicted the presence of intestinal metaplasia with a sensitivity of
93.5% and a specificity of 86.7%, and an irregular/distorted pattern predicted high-
grade dysplasia with a sensitivity of 100% and sensitivity of 98.7%[14]. In a prospective,
blinded, tandem endoscopy study of 65 patients comparing NBI-targeted biopsies to
random biopsies via the Seattle protocol with high definition white light, NBI was able
to identify more patients with dysplasia (57% vs 43%, P < 0.001) and also found high
grades  of  dysplasia  (18%  higher  grade  vs  0%,  P  <  0.001)[15].  In  another  study
comparing results in patient who were first screened for Barrett’s with high definition
white light and then NBI-targeted biopsies at a 6-wk interval, there was no significant
difference in detection of intestinal metaplasia and dysplasia (P  = 0.15),  but NBI
required a significantly fewer number of biopsies to make a diagnosis (3.6 vs 7.6, P <
0.001)[16].  A study comparing computed virtual chromoendoscopy to conventional
chromoendoscopy with acetic  acid,  a  sensitivity  of  83% and 92% for  high grade
intraepithelial neoplasia was found, respectively, with no significant difference bet-
ween the two methods (P = 0.617)[17].
Overall, electronic chromoendoscopy shows high sensitivity for the detection of
high-grade dysplasia in patients with BE and provides a means to more efficiently
biopsy patients. Its ability to detect low grade dysplasia is comparable to that of high-
resolution white light endoscopy. We recommend using electronic chromoendoscopy
given its ease of use (turning on a switch on the endoscope processor), low cost (al-
ready incorporated into the scope technology), and that it meets PIVI thresholds.
CONFOCAL LASER ENDOMICROSCOPY (CLE)
A CLE examination of the gut mucosa is performed using endoscopically delivered
laser light. This light is reflected through a pinhole onto sensors that relay the signals
to a computer, which provides a cross-sectional microscopic image of the mucosa[18].
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Figure 1
Figure 1  A patient with Barrett’s and high-grade dyspalsia with narrow band imaging. A: A segment of Barrett’s esophagus on high definition white light
endoscopy (HDWLE); and B: narrow band imaging (NBI) from a patient with prior long segment disease post two sessions of endoscopic resection, 4 sessions of
radiofrequency ablation, and one session of cryotherapy. The HDWLE did not show any features concerning for dysplasia. The NBI shows an area of disrupted
vessels (upper yellow arrow, lower white arrow) concerning for dysplasia.
CLE is almost analogous to looking real time at a microscope during the endoscopy
exam. There is limited data on the learning curve for use of CLE in Barrett’s, but it
appears favorable[19]. This allows for detailed analysis of the intestinal mucosa and in
vivo histology during ongoing endoscopy[20]. CLE has shown high accuracy rates (85%-
94%)  for  the  detection  of  high-grade  dysplasia  and  a  sensitivity  of  80%  in  the
identification of advanced neoplasia with good interobserver agreement[20,21]. In an ex
vivo study, CLE was shown to have positive and negative predictive values for high-
grade dysplasia/early cancer of 44% and 83%, respectively[22]. When combined with
high-definition white light endoscopy, probe-based CLE was able to detect all cases of
high-grade dysplasia/early cancer in this study, but this was not statistically sig-
nificant compared to these imaging methods alone[23].
Currently endoscope-based CLE (e-CLE) is  not available for use in the United
States, but the probe-based CLE (pCLE) version (Cellvizio, Mauna Kea Technologies,
MA, United States) is. The pCLE version images a small area at a time and thus has a
narrow field of view. Thus, it is cumbersome to use in long segments of Barrett’s
where advanced imaging is more of a need vs short segments. In our practice we find
CLE to be helpful when wanting to examine a specific area if considering a biopsy vs
endoscopic resection, however its routine use for surveillance is limited given its
narrow field of view; especially since it does not meet PIVI thresholds. It should be
noted that CLE also requires intravenous fluorescein which has been reported to be
safe in GI procedures[23].
VOLUMETRIC LASER ENDOMICROSCOPY (VLE)
VLE (NvisionVLE, Ninepoint Medical, Bedford, MA, USA) is the latest advanced
imaging technology in Barrett’s. It is second-generation optical coherence tomography
using infrared light  to produce real-time,  high-resolution,  cross-sectional  micro-
structure  imaging  of  tissue[24].  VLE  can  scan  a  6-cm length  of  the  esophagus  in
approximately 90 s,  providing surface and subsurface wide-field cross-sectional
imaging with an axial resolution of 7 μm, and to a depth of 3 mm[25]. Ex-vivo studies
comparing  VLE features  to  endoscopic  resection  specimens  have  demonstrated
sensitivities of 86%-90% and specificities of 88%-93% for the detection of dysplasia in
BE[26]. The benefits to VLE is that an entire segment of Barrett’s can be imaged in a
short  period  of  time,  abnormalities  can  be  laser  marked  for  targeting,  the
interobserver variability among experts is limited[27], and the learning curve for image
interpretation appears favorable[28]. In a large retrospective study comparing the dys-
plasia yield in BE’s patients undergoing Seattle protocol biopsies, VLE without laser
markings, and VLE with laser markings (VLEL), both VLE with and without laser
marking had statistically significant differences in dysplasia yield compared to Seattle
protocol,  (14% vs  1%, P  = 0.001) and (11% vs  1%, P  = 0.003),  respectively[25].  VLE
appears to be a safe form of advanced imaging. In a case series on 52 patients, the
safety and feasibility of the NVision VLE system was assessed. Of the 52 patients
undergoing VLE, only 2 minor adverse events were reported which includes mucosal
lacerations that did not require therapy or intervention[29]. VLE does not appear to
significantly increase endoscopic risk to patient but can lead longer procedure times,
estimated 22 ± 6 min standard deviation, which can be of anesthetic concern[30].
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The downside to VLE is that a large amount of information is presented that may
be overwhelming or  time consuming to  interpret.  Artificial  intelligence  (AI)  te-
chnology has been developed that has recently been released and is under study in a
prospective  fashion[31].  This  may  help  physicians  process  the  large  amount  of
information and images that are presented at one time. The AI technology is termed
intelligent real-time image segmentation (IRIS) and highlights three VLE features
associated with dysplasia . The three features of dysplasia include hyper-reflective
surface, hypo-reflective structures, and a lack of layering. A hyper-reflective surface
indicates a high surface signal (appears darker) relative to the subsurface. The image
feature is represented as a pink color bar at the tissue surface. The lack of layering
image feature is represented by an orange color bar at the exterior edge of the VLE
image  space.  The  hypo-reflective  structure  (usually  glandular  structures)  is  re-
presented by a blue image overlay on top of the structure. IRIS displays an en face
image of the scanned esophagus. There is also a luminal en face view that reconstructs
the  Barrett’s  segment  in  regard  to  the  three  features.  These  allow for  easier  id-
entification of overlap between the three colors and is high yield for areas that could
be dysplastic.  Figures  2-4  show VLE images with IRIS in  patients  with Barrett’s
esophagus and high-grade dysplasia.  Figure 5 shows the endoscopy view of the
targeted laser marks (upper yellow arrow, lower yellow arrow) placed using vo-
lumetric laser endomicroscopy.
Prospective in vivo studies are needed looking at the sensitivity and specificity of
VLE in dysplasia detection for BE. A prospective multi-center study examining this
has been completed and we are  awaiting results[32].  We suspect  VLE is  the most
sensitive tool for the detection of dysplasia in BE. For reference, acetic acid chro-
moendoscopy, narrow band imaging and endoscopic CLE have been shown to have
high sensitivity of close to 90% in various studies. The VLE scoring system is evolving
as quickly as the technology is being developed. The traditional current VLE scoring
system (OCT-SI) generates a dysplasia score after the combination of 2 independent
criteria (surface to subsurface signal intensity and glandular archi-tecture). The novel
VLE diagnostic algorithm (VLE-DA) where a segment of BE is first characterized as
having  complete  or  partial  effacement,  then  further  categorized  by  subsurface
intensity and number of atypical glands respectively. In a head to head comparison
for  the  detection of  dysplasia,  pCLE,  OCT-SI  and VLE-DA were  evaluated.  The
sensitivity for pCLE was 76% (95%CI: 59-88), for OCT-SI was 70% (95%CI: 52-84) and
for  VLE-DA  was  86%  (95%CI:  69-96)[33].  Finally  cost  utility  studies  are  needed
comparing the benefit of finding dysplasia and preventing cancer and its associated
costs.
CONCLUSION
Advanced imaging in BE can be useful in management of these patients if it helps
increase yield of dysplasia detection or help change management in a procedure. The
decision to perform these procedures ultimately depends on if the benefit outweighs
the cost and added time performing the procedure. In our practice the added benefits
of narrow band imaging and volumetric laser endomicroscopy outweighs the costs
and added time and thus we have incorporated this into our Barrett’s surveillance
routine.
Future  research  may dictate  which  advanced  imaging  techniques  become in-
corporated in the gastrointestinal society guidelines, but for now if the sensitivity,
specificity, and cost of an exam is acceptable locally for a center/endoscopic imaging
expert[34], then the advanced imaging tool is generally acceptable and thus worth the
squeeze!
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Figure 2
Figure 2  Volumetric laser endomicroscopy with artifical intelligence from the same patient as in Figure 1 with an en-face view showing an area of overlap
(yellow arrow) between three features of dysplasia (orange is lack of layering, blue is glandular structures, and pink is a hyper-reflective surface).
Figure 3
Figure 3  Volumetric laser endomicroscopy from the same patient showing cross-sectional view of the area of overlap (yellow arrow 5.73” 5.41”) between
three features of dysplasia (orange is lack of layering, blue is glandular structures, and pink is a hyper-reflective surface).
Figure 4
Figure 4  Volumetric laser endomicroscopy with artificial intelligence showing an up close snap shot of the abnormal area of overlap between three
features of dysplasia (orange is lack of layering, blue is glandular structures, and pink is a hyper-reflective surface).
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Figure 5
Figure 5  Endoscopy view of the targeted laser marks (upper yellow arrow, lower yellow arrow) placed using volumetric laser endomicroscopy. This
corresponds to the same area highlighted by narrow band imaging. The pathology showed high-grade dysplasia.
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